Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
51
52
Next >
7 Stocks to Buy and Hold for a Lifetime of Wealth
October 19, 2023
The best way to live a stress-free life and build wealth in the long term is to choose stocks to buy and hold. Here are 7 that fit the bill.
Via
InvestorPlace
How Consumer Goods Will Survive the Negative Impacts of Ozempic
October 18, 2023
Ozempic is a popular drug doctors are prescribing to millions of patients to fight obesity and diabetes. CNBC reports that in the first six months of 2023 alone, Ozempic sales have grown by 58%.
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
3 Stock-Split Stocks With 110% to 696% Upside, According to Select Wall Street Analysts and Pundits
October 18, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three stock-split stocks select people on Wall Street believe offer...
Via
The Motley Fool
Why Novo Nordisk Stock Raced Higher Today
October 13, 2023
Wegovy and Ozempic should continue to be hot items at the pharmacy.
Via
The Motley Fool
This Is What Whales Are Betting On Novo Nordisk
October 13, 2023
Via
Benzinga
Why Shares of Ardelyx Were Down Wednesday
October 11, 2023
The company's hopes for approval of a drug to treat chronic kidney disease took a hit.
Via
The Motley Fool
While growth is established for NYSE:NVO, the stock's valuation remains reasonable.
October 17, 2023
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via
Chartmill
Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.
October 17, 2023
What's good for Novo Nordisk's Ozempic is also good for Eli Lilly's Mounjaro.
Via
The Motley Fool
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
October 16, 2023
Investors should brush off Ozempic selloff fears and dive into tasty food and beverage stocks that have been oversold in 2023.
Via
InvestorPlace
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
October 16, 2023
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale.
Via
Benzinga
Barron's Weekend Stock Picks: Truist Financial, Groupon And Nvidia's Rising Stock
October 15, 2023
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.
Via
Benzinga
1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs
October 14, 2023
Can concerns about side effects derail the growth of these incredibly popular drugs?
Via
The Motley Fool
Johnson & Johnson Stock: Is Now the Time to Sell?
October 14, 2023
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff
Via
InvestorPlace
Are Ozempic and Similar Treatments Impacting Food and Beverage Stocks? Here's What Pepsi's CFO Said About It
October 14, 2023
PepsiCo's Q3 earnings may have shed some light on the long-standing speculation about Ozempic's impact on consumer staples.
Via
The Motley Fool
Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
October 14, 2023
Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Novo Nordisk has revised its full-year outlook.
Via
Benzinga
Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review
October 13, 2023
The major indexes stalled at key levels amid weak breadth.
Via
Investor's Business Daily
Ozempic Weight Loss Drug Maker Is Making Money Hand Over Fist - And Just Raised Its Profit Forecast
October 13, 2023
Novo Nordisk A/S (NYSE: NVO) raised its FY23 guidance as sales of its block
Via
Benzinga
Momo Buys On Iran Hinting At Second Front And Israel Issuing An Impossible Evacuation Order
October 13, 2023
To gain an edge, this is what you need to know today.
Via
Benzinga
Why WW International Stock Was Bulking Up This Week
October 12, 2023
Its leading proponent effectively endorsed the company's recent pivot.
Via
The Motley Fool
Novo Nordisk's Kidney Outcomes Trial Has Broad Industry Implications
October 12, 2023
Novo Nordisk A/S (NYSE: NVO) shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on
Via
Benzinga
ChatGPT Parent OpenAI Aims At Budget-Friendly AI Innovations, Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany: Today's Top Stories
October 12, 2023
Bloomberg Apple and Suppliers Face Unanticipated Sales Slump Despite New Launches
Via
Benzinga
Topics
Artificial Intelligence
Supply Chain
Exposures
Artificial Intelligence
Supply Chain
Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany
October 12, 2023
Germany's federal drug regulator, BfArM, has warned pharmacies and drug distributors in response to discovering counterfeit batches of Novo Nordisk's (NYSE: NVO) diabetes
Via
Benzinga
7 Affordable Stocks to Invest in as America’s Population Ages
October 12, 2023
Stocks for an aging population include some surprisingly youthful products and firms not commonly associated with seniors.
Via
InvestorPlace
Eli Lilly To Fly Higher? Fund Manager Gary Black Envisions Blockbuster Potential For Diabetes Drug Mounjaro
October 12, 2023
Lilly stock has been on a tear this year, thanks to the huge potential its GLP-1 agonist Mounjaro promises.
Via
Benzinga
Tempest Therapeutics, Microsoft, Birkenstock, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
October 11, 2023
Major U.S. stock indices ended in the green on Wednesday, with the Nasdaq Composite marking notable gains of nearly 100 points.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Investors Punished Baxter International Stock Today
October 11, 2023
The latest data from the lab could spell trouble for the company.
Via
The Motley Fool
The Weight Loss Drug Gold Mine
October 11, 2023
U.S. healthcare providers wrote more than 9 million prescriptions for GLP-1 drugs in the final quarter of 2022, as demand soared for the blockbuster treatments. And one key company is reaping the...
Via
Talk Markets
Why Dialysis Stocks Plunged Today
October 11, 2023
Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here's what investors need to know.
Via
The Motley Fool
Ozempic Alert: New Trial Causes DaVita (DVA) Stock to Plunge 20%
October 11, 2023
Ozempic may be able to treat kidney disease. This news has sent competitor DaVita into a tailspin as DVA stock plunges.
Via
InvestorPlace
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.